Key result
Cilostazol significantly increased pain-free walking distance by a median of 387 m at 6 months in patients with peripheral arterial disease and intermittent claudication.
Why the study?
The study was conducted to evaluate the real-world effects of cilostazol on pain-free walking distance at 3 and 6 months in patients with peripheral arterial disease and intermittent claudication.
Does cilostazol improve pain-free walking distance in patients with peripheral arterial disease and intermittent claudication?
Observational (n=1,015)
Yes
Does cilostazol improve pain-free walking distance in patients with peripheral arterial disease and intermittent claudication?
In a real-world setting, cilostazol safely improved pain-free walking distance and was associated with blood pressure reductions and positive lifestyle changes in patients with PAD and intermittent claudication.
Answers are grounded in this paper and cite their sources.
May support cilostazol in real-world PAD; extends observational data but leaves open need for RCTs.
OBJECTIVE: to assess the effects of cilostazol on pain-free walking distance in PAD patients with IC at 3 and 6 months in a real world, prospective, observational study. We included 1015 PAD patients presenting with IC (71.3% men, 93.5% white, mean age 69.2 ± 8.7 years). Patients were followed up for 6 months by their physicians. RESULTS: Cilostazol significantly increased pain-free walking distance by a median of 285 and 387 m at 3 and 6 months, respectively (p < 0.01 for all comparisons). This effect was significant for patients 50-74 years (but not for those aged ≥ 75 years) and independent of smoking status, changes in physical activity, comorbidities and concomitant medication for PAD (i.e., acetylsalicylic acid and clopidogrel). Furthermore, significant reductions were observed in systolic (from 139 ± 16 to 133 ± 14 mmHg; p < 0.001) and diastolic blood pressure (from 84 ± 9 mmHg to 80 ± 10 mmHg; p < 0.001). Smoking cessation and increased physical activity were reported by the majority of participants. In conclusion, cilostazol was shown to safely decrease pain symptoms and improve pain-free walking in PAD patients with IC in a real world setting. Benefits also occurred in terms of BP and lifestyle changes.
No takes yet. Share an insight, caveat, or question.
Katsiki et al. (2022) conducted an observational in Peripheral arterial disease with intermittent claudication (n=1,015). Cilostazol vs. Baseline was evaluated on Pain-free walking distance at 6 months (median increase of 387 m, p=<0.01). Cilostazol significantly increased pain-free walking distance by a median of 387 m at 6 months in patients with peripheral arterial disease and intermittent claudication.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: